Calaspargase pegol Disease Interactions
There are 3 disease interactions with calaspargase pegol.
Calaspargase pegol (applies to calaspargase pegol) pancreatitis
Major Potential Hazard, Moderate plausibility.
Cases of pancreatitis have been reported in clinical trials with calaspargase pegol with an incidence as high as 16%. Caution is advised if used in patients with a history of pancreatitis. Inform patients of the signs and symptoms of pancreatitis, which, if left untreated, could be fatal. Assess serum amylase and/or lipase levels to identify early signs of pancreatic inflammation. Discontinue calaspargase pegol if pancreatitis is suspected; if pancreatitis is confirmed, do not resume treatment. Calaspargase pegol is contraindicated in patients with a history of pancreatitis due to any previous asparaginase therapy.
Calaspargase pegol (applies to calaspargase pegol) coagulopathies
Major Potential Hazard, Moderate plausibility. Applicable conditions: Coagulation Defect, Bleeding
Hemorrhage associated with increased prothrombin time (PT), increased partial thromboplastin time (PTT), and hypofibrinogenemia have been reported in patients receiving calaspargase pegol. Evaluate patients with signs and symptoms of hemorrhage with coagulation parameters including PT, PTT, fibrinogen. Consider appropriate replacement therapy in any patients with severe or symptomatic coagulopathy. The use of calaspargase pegol is contraindicated in patients with any history of serious hemorrhagic events during a previous L-asparaginase therapy.
Calaspargase pegol (applies to calaspargase pegol) hepatic impairment
Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
The use of calaspargase pegol is contraindicated in patients with severe hepatic impairment. Caution and monitoring is advised in patients with liver impairment as hepatotoxicity and abnormal liver function, including elevations of transaminase, bilirubin (direct and indirect), reduced serum albumin, and plasma fibrinogen can occur. Evaluate bilirubin and transaminases at least weekly, during cycles of treatment that include calaspargase pegol, through 6 weeks after the last dose. In the event of serious liver toxicity, discontinue treatment and provide supportive care.
Switch to professional interaction data
Calaspargase pegol drug interactions
There are 410 drug interactions with calaspargase pegol.
Calaspargase pegol alcohol/food interactions
There is 1 alcohol/food interaction with calaspargase pegol.
More about calaspargase pegol
- calaspargase pegol consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: miscellaneous antineoplastics
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.